TTPH - Tetraphase Pharma Summary, Stock Quote and News

0.4005 -0.012 (-2.91%)

Data as of Jul 22, 2019

Prev. Close 0.4125
Price Open 0.43
Volume 347,811
Day's Range 0.4004 - 0.43
52 Wk Range 0.4004 - 3.66
50 Day Moving Avg. 0.67
PE Ratio 0
Shares Outstanding 54.26M
Market Cap 21.73M

Trade TTPH stock with recommended broker Ally Invest. Commissions as low as $3.95.

Analyst Rating View All Ratings

Date	Action	Current	Target
3/18/19	Downgrades	BuyHold
9/06/18	Upgrades	Speculative BuyBuy
8/28/18	Maintains	BuyBuy	7.0

The Daily Biotech Pulse: Roche's Flu Drug Aces Late-Stage Trial, Acura Outlicenses Pain Medication, Neuronetics Gets New Finance Chief Shanthi RexalineWed, 03 Jul 2019 07:31:07 -0400
The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO Shanthi RexalineThu, 27 Jun 2019 07:26:01 -0400
The Daily Biotech Pulse: Decision Day For Regeneron-Sanofi, Vermillion Offering, PDL BioPharma CFO to Depart Shanthi RexalineWed, 26 Jun 2019 07:19:56 -0400
The Daily Biotech Pulse: Genfit NASH Drug In China, Conatus Explores Sale, Gilead Stitches Up Immuno-Oncology Partnership Shanthi RexalineTue, 25 Jun 2019 07:15:30 -0400
Tetraphase Pharma Highlights New XERAVA Studies Benzinga NewsdeskMon, 24 Jun 2019 07:17:06 -0400
The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Shanthi RexalineTue, 18 Jun 2019 07:31:03 -0400
The Daily Biotech Pulse: Savara Slumps On Flunked Trial, NuCana Takes Off, Tetraphase Downsizes Shanthi RexalineThu, 13 Jun 2019 07:44:09 -0400
Tetraphase Pharma To Present Data At Upcoming American Society for Microbiology Microbe 2019 Annual Meeting Benzinga NewsdeskThu, 13 Jun 2019 07:03:10 -0400
UPDATE: Tetraphase Sees Workforce, R&D Expense Reduction Resulting In Annualized Savings Of ~$8M Benzinga NewsdeskWed, 12 Jun 2019 16:02:27 -0400
Tetraphase Pharma Reports Corporate Reorg To Maximize XERAVA Commercial Opportunity Benzinga NewsdeskWed, 12 Jun 2019 16:01:53 -0400
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

New Studies Highlight Activity of XERAVA™ Against Gram-Negative and Gram-Positive Clinical Isolates, Including Multidrug-Resistant Pathogens Business WireJun 24, 2019
Robbins Arroyo LLP: Tetraphase Pharmaceuticals, Inc. (TTPH) Accused of Misleading Shareholders Business WireJun 13, 2019
Tetraphase Pharmaceuticals Highlights Data at Upcoming American Society for Microbiology Microbe 2019 Annual Meeting Business WireJun 13, 2019
Tetraphase Pharmaceuticals Announces Corporate Reorganization Aimed at Maximizing XERAVA™ (Eravacycline) Commercial Opportunity Business WireJun 12, 2019
Tetraphase Pharmaceuticals Announces New XERAVA™ (eravacycline) Data at the 39th Annual Surgical Infection Society Meeting Business WireJun 10, 2019
Tetraphase Pharmaceuticals to Present Data at the 39th Annual Meeting of the Surgical Infection Society Business WireMay 29, 2019
Tetraphase Pharmaceuticals Reports First Quarter 2019 Financial Results and Highlights Recent Corporate Developments Business WireMay 08, 2019
Tetraphase Pharmaceuticals to Present Data at the 22nd Annual MAD-ID Meeting Business WireMay 02, 2019
Tetraphase Pharmaceuticals to Host First Quarter 2019 Financial Results Conference Call Business WireMay 01, 2019
Tetraphase Pharmaceuticals to Participate in Upcoming Investor Conferences Business WireApr 30, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Tetraphase down 4% after hours on downsizing plan Seeking AlphaJun 12, 2019
Tetraphase up 11% on retrospective Xerava data Seeking AlphaJun 10, 2019
Key events next week - healthcare Seeking AlphaMay 31, 2019
Tetraphase Pharmaceuticals' (TTPH) CEO Guy Macdonald on Q1 2019 Results - Earnings Call Transcript Seeking AlphaMay 08, 2019
Tetraphase Pharmaceuticals (TTPH) Reports Q1 Loss, Misses Revenue Estimates ZacksMay 08, 2019
STM, OPTT among premarket gainers Seeking AlphaApr 03, 2019
Seelos Therapeutics leads healthcare gainers; Vermillion and Chiasma among the losers Seeking AlphaMar 29, 2019
Key events next week - healthcare Seeking AlphaMar 21, 2019
BTIG likes Arcus Bio in premarket analyst action Seeking AlphaMar 18, 2019
Tetraphase Pharmaceuticals, Inc. (TTPH) CEO Guy Macdonald on Q4 2018 Results - Earnings Call Transcript Seeking AlphaMar 15, 2019
{{ story.title }} {{ story.author }}{{ story.created }}

Show more Loading articles...

Earnings View Earnings

Q1 2019	EST	Actual	Surprise
EPS:	-0.390	-0.360	0.0300
Rev:		1.27M

Q2 2019	EST	Actual	Surprise
EPS:	Expected 2019-08-01
Rev:	Expected 2019-08-01

Fastest Market News Application
You'll Hear It First On Pro

Company Profile

Visit company website

Brokerage Center

Compare All Online Brokerages

Market Overview

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners

Membership is Free

What are you waiting for? Sign up now!

Free Account Login

Market Overview

Tickers

Articles

Keywords

Tetraphase Pharma TTPH:NASDAQ

Analyst Rating View All Ratings

Earnings View Earnings

Company Profile

Brokerage Center

Popular Channels

Tools & Features

About Benzinga

Benzinga Partners